<DOC>
	<DOCNO>NCT01265264</DOCNO>
	<brief_summary>The purpose study determine whether ulodesine allopurinol combine 12 week effective treat gout patient adequately respond allopurinol alone .</brief_summary>
	<brief_title>Study Evaluate sUA Lowering Activity , Safety Efficacy Oral Ulodesine Added Allopurinol</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Age ≥ 18 &lt; 70 year Baseline sUA ≥ 6.0 mg/dL least 2 week treatment stable 300 mg dose allopurinol Documented diagnosis gout accord American Rheumatism Association Preliminary Criteria Diagnosis Gout Be willing able take colchicine 0.6 mg per day naproxen 220250 mg twice daily prophylaxis gout flare , need , single daily dose proton pump inhibitor prevent gastrointestinal discomfort Female participant must : Be sexually abstinent Be surgically sterile Be postmenopausal stable contraception Male participant must : Be sexually abstinent Be &gt; 1 year postvasectomy Using condom spermicide partner meet female requirement Unable tolerate 300 mg allopurinol Unable tolerate colchicine 0.6 mg per day naproxen 220250 mg twice daily Prior participation clinical study BCX4208 Gout flare Screening Period resolve less 2 week prior first treatment BCX4208 placebo ( exclusive chronic synovitis/ arthritis ) Unstable angina , symptomatic arrhythmia , sign symptom compatible New York Heart Association Class III Class IV heart failure , history long QT syndrome , QTc interval &lt; 350 msec &gt; 475 msec Poorly control hypertension ( SBP &gt; 160 mmHg DBP &gt; 100 mmHG Screening Baseline ) Moderate severe renal impairment and/or calculate creatinine clearance &lt; 60 mL/min ( CockroftGault method ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2.0 x ULN CD4+ cell count flow cytometry &lt; 500 cells/mm3 Hemoglobin &lt; 10 g/dL &gt; 18 g/dL male &lt; 10 g/dL &gt; 17 g/dL female White blood cell count &lt; 3.7 x 109/L &gt; 11 x 109/L Female subject pregnant , breastfeeding , plan pregnancy within next 4 month Positive serology hepatitis B surface antigen hepatitis C HIV type 1 Immunocompromised systemic immunosuppressive medication antirheumatic drug ( include anakinra adrenocorticotropic hormone ) Screening Day 92 Azathioprine 6mercaptopurine within 14 day first dose allopurinol Hydrochlorothiazide dose &gt; 50 mg per day Screening Day 92 Use herbal/dietary supplement Screening Day 92 Recipient live attenuate vaccine within 6 week Screening Uric acidlowering drug allopurinol Screening Day 92 Systemic corticosteroid within 4 week prior Day 1 ( include pulmonary nasal inhaler contain corticosteroid , ophthalmic corticosteroid , joint injection , low potency topical steroid ) Investigational drug within 30 day prior sign ICF study Clinically significant relevant drug allergy Chronic recurrent infection ( ≥ 3 infection site within 12 month ) Cancer within 12 monthsExcept nonmelanomatous localized skin cancer completely excise cured carcinomainsitu uterine cervix subject previously treat prostate breast cancer currently stable chemo therapy within last year prior screen . Alcohol drug abuse within 12 month sign ICF , current substance dependence abuse Other medical condition , opinion PI , would jeopardize safety study subject impact validity study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Gout</keyword>
	<keyword>hyperuricemia</keyword>
	<keyword>arthritis</keyword>
	<keyword>joint disease</keyword>
	<keyword>allopurinol</keyword>
</DOC>